Get the Stockscreener App
12.58
2.95%
0.36
Dyne Therapeutics Inc stock is traded at $12.58, with a volume of 2.30M.
It is up +2.95% in the last 24 hours and up +36.59% over the past month.
Dyne Therapeutics Inc is a clinical-stage neuromuscular disease company focused on discovering and advancing life-transforming therapeutics for people living with genetically driven neuromuscular diseases. Its FORCE platform develops targeted therapeutics that are designed to overcome limitations in delivery to muscle tissue and the central nervous system, or CNS. Its FORCE platform therapeutics consist of a payload that is rationally designed to target the genetic basis of the disease are seeking to treat, a linker, and an antigen-binding fragment, that attaches to the payload using the linker. Its Pipeline includes DYNE-101, DYNE-251, DYNE-302, and DYNE-401.
See More
Previous Close:
$12.22
Open:
$12.39
24h Volume:
2.30M
Relative Volume:
0.81
Market Cap:
$1.79B
Revenue:
-
Net Income/Loss:
$-412.89M
P/E Ratio:
-3.2591
EPS:
-3.86
Net Cash Flow:
$-361.93M
1W Performance:
+1.62%
1M Performance:
+36.59%
6M Performance:
-10.21%
1Y Performance:
-72.35%
1-Day Range:
$12.23
$12.91
1-Week Range:
$11.64
$12.91
52-Week Range:
$6.36
$46.80
Dyne Therapeutics Inc Stock (DYN) Company Profile
Name
Dyne Therapeutics Inc
Sector
Industry
Phone
(781) 786-8230
Address
1560 TRAPELO ROAD, WALTHAM
Compare DYN with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
DYN
Dyne Therapeutics Inc
|
12.58 | 1.75B | 0 | -412.89M | -361.93M | -3.86 |
|
VRTX
Vertex Pharmaceuticals Inc
|
395.12 | 99.96B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
589.48 | 60.83B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
454.38 | 59.89B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
660.00 | 40.47B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
313.67 | 37.96B | 3.81B | -644.79M | -669.77M | -6.24 |
Dyne Therapeutics Inc Stock (DYN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jun-24-25 | Initiated | Bernstein | Mkt Perform |
| Jun-11-25 | Resumed | Raymond James | Outperform |
| Jun-02-25 | Resumed | Oppenheimer | Outperform |
| May-29-25 | Initiated | Evercore ISI | Outperform |
| Mar-12-25 | Initiated | BMO Capital Markets | Outperform |
| Mar-07-25 | Initiated | Scotiabank | Sector Outperform |
| Dec-13-24 | Initiated | Robert W. Baird | Outperform |
| Nov-26-24 | Initiated | RBC Capital Mkts | Outperform |
| Oct-24-24 | Downgrade | JP Morgan | Overweight → Neutral |
| May-21-24 | Reiterated | Chardan Capital Markets | Buy |
| Apr-30-24 | Initiated | Morgan Stanley | Overweight |
| Feb-20-24 | Initiated | H.C. Wainwright | Buy |
| Feb-27-23 | Upgrade | Raymond James | Outperform → Strong Buy |
| Feb-15-23 | Initiated | Oppenheimer | Outperform |
| Jan-26-23 | Initiated | Guggenheim | Buy |
| Jul-20-22 | Initiated | Chardan Capital Markets | Buy |
| Jul-12-22 | Initiated | Raymond James | Outperform |
| Oct-12-20 | Initiated | JP Morgan | Overweight |
| Oct-12-20 | Initiated | Jefferies | Buy |
| Oct-12-20 | Initiated | Piper Sandler | Overweight |
| Oct-12-20 | Initiated | Stifel | Buy |
View All
Dyne Therapeutics Inc Stock (DYN) Latest News
Dyne Therapeutics Inc. Recovery Likely Here’s What Data ShowsTrade Risk Assessment & Safe Entry Momentum Stock Tips - beatles.ru
Dyne Therapeutics Inc. Approaches Support With Recovery in SightJuly 2025 Trends & Verified Momentum Stock Watchlist - thegnnews.com
Dyne Therapeutics (DYN) Maintains Hold Rating, $12 Price Target - AInvest
What Technical Tools Say About Dyne Therapeutics Inc. RecoveryJuly 2025 Analyst Calls & Risk Managed Trade Strategies - beatles.ru
Myotonic Dystrophy Pipeline 2025: MOA, ROA, FDA-Approved Drugs, and Clinical Trial Progress Assessment by DelveInsight | Dyne Therapeutics, Avidity Biosciences, Harmony Biosciences, AMO Pharma, Lupin - Barchart.com
Dyne Therapeutics Shares Rise 3.6% After FDA Grants Breakthrough Therapy Status - MSN
Dyne Therapeutics Receives FDA Breakthrough Therapy Designation for Duchenne Muscular Dystrophy Therapy - Yahoo Finance
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Dyne Therapeutics, Inc. - DYN - GlobeNewswire Inc.
Should value investors consider Dyne Therapeutics Inc.July 2025 PostEarnings & Safe Capital Growth Stock Tips - thegnnews.com
Pomerantz LLP investigates Dyne Therapeutics for potential securities fraud. - AInvest
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Dyne Therapeutics, Inc.DYN - PR Newswire
Why is Dyne Therapeutics Inc. stock going up2025 EndofYear Setup & Consistent Profit Alerts - thegnnews.com
Can Dyne Therapeutics Inc. expand its profit margins2025 Volatility Report & Comprehensive Market Scan Reports - 선데이타임즈
Dyne Therapeutics Advances DMD Treatment with DYNE-251 Study - MSN
Short Interest Drops in Dyne Therapeutics Inc. After RallyJuly 2025 Setups & High Return Stock Watch Alerts - sundaytimes.kr
Dyne Therapeutics Inc. Shows Risk Reward Favoring UpsideLow Capital High Return Stock Plans Reviewed - 선데이타임즈
Dyne Therapeutics Trading Resumes - AInvest
Is Dyne Therapeutics Reaching New Heights? - StocksToTrade
Dyne Therapeutics price target lowered to $13 from $34 at Oppenheimer - TipRanks
Oppenheimer Lowers Dyne Therapeutics (DYN) Price Target to $13.00 | DYN Stock News - GuruFocus
Oppenheimer Lowers Dyne Therapeutics (DYN) Price Target to $13.0 - GuruFocus
Dyne Therapeutics (DYN) Earns Breakthrough Therapy Status for DY - GuruFocus
Dyne Reports Wider Loss in Fiscal Q2 - AOL.com
Dyne Therapeutics stock gains as DYNE-251 receives FDA breakthrough designation - Investing.com Canada
Dyne Therapeutics (DYN) Gains FDA Breakthrough Status for DYNE-2 - GuruFocus
Dyne Therapeutics stock rises after FDA grants breakthrough therapy status By Investing.com - Investing.com Australia
Dyne Therapeutics stock rises after FDA grants breakthrough therapy status - Investing.com
Dyne gets FDA breakthrough therapy status for DMD therapy - Seeking Alpha
Dyne Therapeutics (DYN) Earns Breakthrough Therapy Status for DYNE-251 - GuruFocus
Dyne Therapeutics Gains FDA Breakthrough Designation for DYNE-251 - TipRanks
Dyne Therapeutics Announces Breakthrough Therapy Designation For DYNE-251 - Nasdaq
Dyne Therapeutics Announces FDA Breakthrough Therapy Designation - GuruFocus
Dyne Therapeutics Announces FDA Breakthrough Therapy Designation For Dyne-251 In Duchenne Muscular Dystrophy - TradingView
Dyne Therapeutics Receives FDA Breakthrough Therapy Designation for DYNE-251 in Duchenne Muscular Dystrophy - Quiver Quantitative
Dyne Therapeutics Announces FDA Breakthrough Therapy Designation for DYNE-251 in Duchenne Muscular Dystrophy (DMD) - The Manila Times
Dyne Therapeutics Announces FDA Breakthrough Therapy - GlobeNewswire
Dyne Therapeutics: Promising Advancements and FDA Support Drive Buy Rating - TipRanks
What makes Dyne Therapeutics Inc. stock price move sharplyAchieve breakthrough profits with expert advice - Jammu Links News
What is Dyne Therapeutics Inc. company’s growth strategyTremendous growth opportunities - Jammu Links News
Is it the right time to buy Dyne Therapeutics Inc. stockMarket-beating returns - Jammu Links News
Why is Dyne Therapeutics Inc. stock attracting strong analyst attentionAchieve breakthrough gains with expert advice - Jammu Links News
Should I hold or sell Dyne Therapeutics Inc. stock in 2025Build wealth steadily with proven investment techniques - Jammu Links News
What is the risk reward ratio of investing in Dyne Therapeutics Inc. stockAchieve breakthrough investment performance - Jammu Links News
How many analysts rate Dyne Therapeutics Inc. as a “Buy”Unlock powerful market insights for success - jammulinksnews.com
Does Dyne Therapeutics (DYN) Have the Potential to Rally 285.57% as Wall Street Analysts Expect? - MSN
Dyne Therapeutics Reports Second Quarter 2025 Financial Results and Recent Business Highlights - ADVFN Brasil
Pomerantz Investigates Dyne Therapeutics for Securities Fraud. - AInvest
Stifel Downgrades Dyne Therapeutics to Buy, Lowers PT to $36. - AInvest
Stifel lowers Dyne Therapeutics stock price target to $36 on endpoint changes - Investing.com Canada
Dyne Therapeutics (DYN) Gets a Buy from Scotiabank - The Globe and Mail
Dyne Therapeutics (DYN) Keeps 'Outperform' Rating Amid RBC Capital Price Target Cut to $23.00 - AInvest
Dyne Therapeutics Inc Stock (DYN) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.94%
1.72%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):